Phase 1 Prostate Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have signed the written consent form agreeing to take part in the trial
• People aged 18 years or older, of any sex
• People with a life expectancy of at least 12 weeks
• People with a general health and activity level rated as 0 or 1 on a standard medical scale called the ECOG scale, meaning they are fully active or have only minor restrictions on physical activity
• People who have been diagnosed with locally advanced or metastatic breast cancer, ovarian cancer, prostate cancer, or another advanced solid tumour through laboratory testing, whose cancer has continued to grow despite trying all standard available treatments
• People who are willing to provide a tumour tissue sample (either freshly frozen or previously stored) or a blood sample, so that genetic testing can check for certain DNA repair gene changes (such as BRCA mutations or related changes)
• People who have at least one tumour that can be measured on scans according to standard criteria (called RECIST v1.1)
• People who do not have serious blood, heart, lung, liver, or kidney conditions beyond their cancer diagnosis
• People whose organ function and bone marrow function meet the required levels (confirm with trial site)

Who may not be able to join:

• People who have previously used or are currently using a type of drug called a POLQ inhibitor
• People who have had a serious allergic reaction to the active ingredient or any component of the study drug SYN818
• People who have cancer that has spread to the brain or the lining around the brain and spine, where this has not been well controlled or is causing symptoms
• People who have had another cancer (other than the one being studied) in the past 5 years, unless it was a localised cancer considered fully cured or free of disease for at least 3 years (such as certain skin cancers, early bladder cancer, or certain in situ cancers)
• People who have, or show signs of having, a bone marrow condition called Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukaemia (AML)
• People who have difficulty swallowing, ongoing nausea and vomiting, or digestive conditions that affect how the body absorbs medicines (such as Crohn's disease, ulcerative colitis, or short bowel syndrome)
• People who have had major surgery or a serious injury within 4 weeks before the start of the study, or who have major surgery planned during the trial, and have not yet recovered from related side effects
• People who have taken certain medications within 2 weeks before starting the trial that strongly affect how the body processes the study drug (called potent CYP3A4, BCRP, or P-gp inhibitors or inducers), or who would need to keep taking these during the trial
• People with serious overall health conditions, significant abnormal test results, or other circumstances that the trial doctor considers would make participation unsuitable

Important: Always verify eligibility with the trial site directly before applying.